CRL stock icon

Charles River Laboratories
CRL

$217.21
0.16%
 

About: Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Employees: 21,400

0
Funds holding %
of 6,665 funds
0
Analysts bullish %
of 10 analysts
0
News positive %
of 10 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

88% more funds holding in top 10

Funds holding in top 10: 8 [Q4 2023] → 15 (+7) [Q1 2024]

58% more first-time investments, than exits

New positions opened: 87 | Existing positions closed: 55

14% more capital invested

Capital invested by funds: $12.3B [Q4 2023] → $14B (+$1.75B) [Q1 2024]

11% more repeat investments, than reductions

Existing positions increased: 247 | Existing positions reduced: 222

5% more funds holding

Funds holding: 619 [Q4 2023] → 651 (+32) [Q1 2024]

0.24% less ownership

Funds ownership: 109.99% [Q4 2023] → 109.75% (-0.24%) [Q1 2024]

47% less call options, than puts

Call options by funds: $49.4M | Put options by funds: $93.7M

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$215
1%
downside
Avg. target
$263
21%
upside
High target
$290
34%
upside

10 analyst ratings

positive
70%
neutral
30%
negative
0%
TD Cowen
Charles Rhyee
5%upside
$228
Hold
Maintained
13 May 2024
Baird
Eric Coldwell
24%upside
$270
Outperform
Maintained
10 May 2024
Argus Research
David Toung
34%upside
$290
Buy
Maintained
18 Mar 2024
Evercore ISI Group
Ross Muken
22%upside
$265
Outperform
Maintained
15 Feb 2024
UBS
Dan Brennan
34%upside
$290
Buy
Maintained
15 Feb 2024

Financial journalist opinion

Based on 10 articles about CRL published over the past 30 days